Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus DUOBRII.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus DUOBRII.
ARAZLO vs DUOBRII
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Duobrii (halobetasol propionate and tazarotene) is a combination of a corticosteroid and a retinoid. Halobetasol propionate is a high-potency corticosteroid that acts via glucocorticoid receptors to induce anti-inflammatory, antiproliferative, and immunosuppressive effects. Tazarotene is a retinoid prodrug that is converted to its active form, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) to modulate gene expression, thereby reducing keratinocyte proliferation and promoting differentiation.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply a thin layer to affected areas of the scalp once daily for 8 weeks. For external use only.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Halobetasol propionate: 7.5 hours (terminal); Tazarotene: 9-12 hours (terminal).
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Halobetasol propionate: 60% renal, 40% fecal; Tazarotene: <1% renal, 93% fecal, 6% biliary.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid/Retinoid Combination